Condition (MeSH)
Pseudomyxoma Peritonei
ClinicalTrials.gov lists 37 trials for Pseudomyxoma Peritonei or a narrower condition beneath it. CSL Behring has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
37 of the 37 trials are tagged with Pseudomyxoma Peritonei itself; the rest are tagged with a narrower condition beneath it.
When did Pseudomyxoma Peritonei trials start? (17)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 3 |
| 2024 | 3 |
| 2022 | 1 |
| 2021 | 6 |
| 2019 | 2 |
| 2018 | 1 |
| 2017 | 1 |
| 2016 | 1 |
| 2015 | 3 |
Showing 10 of 17 earlier years.
No forecast is made for this condition: it averages 2.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 22 months across 13 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Pseudomyxoma Peritonei trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 10 |
| Phase 3 | 2 |
| Not applicable | 7 |
| Observational | 12 |
How many Pseudomyxoma Peritonei trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 12 |
| Active, not recruiting | 2 |
| Completed | 11 |
| Terminated | 1 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Pseudomyxoma Peritonei trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| CSL Behring | 1 |
Interventions as named in the registry (15)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Mitomycin C 0.02% | 3 |
| N Acetylcysteine | 2 |
| Gemcitabine/Gemzar | 1 |
| Tislelizumab SC | 1 |
| or carboplatin | 1 |
Showing 5 of 15 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Pseudomyxoma Peritonei trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Hypocalcemia | 22 | 1 |
| Lymphocyte Count Decreased | 18 | 1 |
| Aspartate Aminotransferase (AST) Increased | 17 | 1 |
| Anemia | 15 | 1 |
| Alanine Aminotransferase (ALT) Increased | 14 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Pseudomyxoma Peritonei? (21)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Progression to pseudomyxoma peritonei in patients with low grade appendiceal mucinous neoplasms discovered at time of appendectomy. | American journal of surgery | 2022 | Yes |
| Mucinous appendiceal neoplasms with or without pseudomyxoma peritonei: a review. | ANZ journal of surgery | 2020 | Yes |
| Macroscopic and microscopic characteristics of low grade appendiceal mucinous neoplasms (LAMN) on appendectomy specimens and correlations with pseudomyxoma peritonei development risk. | Annals of diagnostic pathology | 2020 | Yes |
| Long-term Quality of Life After Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei: A Prospective Longitudinal Study. | Annals of surgical oncology | 2018 | Yes |
| Early Postoperative Intraperitoneal Chemotherapy for Low-Grade Appendiceal Mucinous Neoplasms with Pseudomyxoma Peritonei: Is it Beneficial? | Annals of surgical oncology | 2017 | Yes |
Showing 5 of 21 publications.
Prevalence (12)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Pseudomyxoma peritonei | Point prevalence | 1-9 / 100 000 | Europe | Not stated | Unspecified |
| Pseudomyxoma peritonei | Annual incidence | 1-9 / 1 000 000 | Worldwide | Not stated | Exact |
| Pseudomyxoma peritonei | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Pseudomyxoma peritonei | Point prevalence | 1-9 / 100 000 | Europe | Not stated | Exact |
| Pseudomyxoma peritonei | Annual incidence | 1-9 / 1 000 000 | Netherlands | Not stated | Exact |
Showing 5 of 12 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Pseudomyxoma peritonei | 26790 | Exact | Orphadata Science knowledge files, Product 1 |
| Pseudomyxoma peritonei | 26790 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.